Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrated high immunogenicity in preclinical study
On May 13, 2021, CureVac announced together with its collaboration partner GSK, first preclinical data in a rat…
On May 13, 2021, CureVac announced together with its collaboration partner GSK, first preclinical data in a rat…
On May 5, 2021, Moderna announced initial data from its Phase 2 study showing that a single 50…
On May 5, 2021, Hoth Therapeutics announced it has expanded its sponsored research agreement with Virginia Commonwealth University…
On May 5, 2021, CytoDyn announced an agreement to partner with the Albert Einstein Israelite Hospital (AEIH) in…
On Apr. 29, 2021, Pfizer and BioNTech announced they had submitted a variation to the Conditional Marketing Authorization…
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
On Apr. 23, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had awarded…
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
On Apr. 19, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
On Apr. 19, 2021, the Mayo Clinic announced a study that bolstered evidence that colorectal cancer is often…
On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an…
On Apr. 15. 2021, a team of researchers led by the University of Minnesota Medical School announced they…
On Apr. 15, 2021, the World Health Organization (WHO) reported that the world was still failing to develop…
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
On Apr. 14, 2021, the Mayo Clinic announced a new technology platform initiative to deliver the next generation…
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Mar. 30, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that researchers had analyzed…
On Mar. 30, 2021, CytoDyn announced further results from its CD12 trial of severe-to-critically ill patients with COVID-19….
On Mar. 29, 2021, CytoDyn announced that the Republic of the Philippines, Department of Health, Food and Drug…
On Mar. 25, 2021, an international team of scientists announced they had found evidence that SARS-CoV-2 infects cells…
On Mar. 25, 2021, about two decades after first devising a new kind of vaccine, Oregon Health &…
On Mar. 24, 2021, scientists from Washington University School of Medicine in St. Louis announced they had identified…
On Mar. 23, 2021, CytoDyn announced the publication in the Journal of Translational Autoimmunity ‘Case study of a…
On Mar. 22, 2021, Moderna announced that the Philippines had secured 7 million additional doses of COVID-19 Vaccine…
On Mar. 18, 2021, Incyte announced results from the Phase 3 DEVENT study evaluating the efficacy and safety…
On Mar. 15, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced…